Ryvu Therapeutics SA (RVU) AI Stock Analysis

Ryvu Therapeutics SA

(Warsaw:RVU)

Select Model

Rating:37Underperform

Price Target:PLN 27.00▲(59.01% Upside)

Action:initiatedcoverage

Date:09/16/25

The stock score is driven by the company’s persistently weak financial performance—recurring net and cash flow losses, negative ROE, and poor valuation. Revenue growth and high gross margin are positives but are not sufficient to offset sustainability concerns given deep losses and high cash burn. The lack of technical or valuation support, and absence of dividend or positive earnings guidance, anchor the score at the minimum allowed.

Positive Factors

Revenue GrowthThe company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Negative Factors

Profitability ChallengesOngoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Ryvu Therapeutics SA (RVU) vs. SPDR S&P 500 ETF (SPY)

Market Cap: PLN 392.58M
Dividend Yield: ―
Average Volume (3M): 33.34K
Price to Earnings (P/E): -5.6
Beta (1Y): 1.23
Revenue Growth: -11.57%
EPS Growth: 43.60%
Country: PL
Employees: 228
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ryvu Therapeutics SA Business Overview & Revenue Model

Company Description

Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for...

How the Company Makes Money

Ryvu Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through various streams including milestone payments from partnerships with larger pharmaceutical companies, l...

Ryvu Therapeutics SA Financial Statement Overview

Summary

Ryvu Therapeutics SA demonstrates strong revenue growth and improving gross profit margin (near 75%), but persistent negative EBIT, EBITDA, and net margin show unsustainable losses. The cash flow is critically weak, with recurring negative operating and free cash flow, and a negative ROE despite conservative leverage until the most recent period. The company's financial health is challenged by poor profitability and high cash burn, offset only by a solid equity base.

Income Statement

27Negative

Balance Sheet

39Negative

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	61.86M	62.25M	77.97M	46.86M	38.80M	11.19M
Gross Profit	-30.29M	-117.03M	58.39M	29.31M	21.40M	-2.54M
EBITDA	-66.41M	-112.71M	-96.83M	-81.04M	-65.21M	-65.96M
Net Income	-68.00M	-101.23M	-111.44M	-92.11M	-83.78M	-79.08M
Balance Sheet
Total Assets	182.56M	224.44M	378.78M	403.20M	474.98M	228.81M
Cash, Cash Equivalents and Short-Term Investments	74.74M	107.68M	225.40M	233.67M	102.44M	88.23M
Total Debt	74.94M	71.72M	75.51M	906.00K	2.77M	5.07M
Total Liabilities	154.19M	153.69M	234.89M	143.61M	131.59M	59.39M
Stockholders Equity	28.37M	53.83M	143.88M	259.59M	343.39M	161.30M
Cash Flow
Free Cash Flow	-83.75M	-117.75M	-135.38M	-88.11M	12.03M	-69.85M
Operating Cash Flow	-76.54M	-110.28M	-129.48M	-84.55M	21.32M	-57.87M
Investing Cash Flow	23.58M	13.35M	137.16M	-195.54M	690.00K	8.06M
Financing Cash Flow	-3.18M	-3.05M	94.21M	240.83M	-2.46M	-3.17M

Ryvu Therapeutics SA Technical Analysis

Technical Analysis SentimentNegative

Last Price16.98

Price Trends

50DMA17.05Negative

100DMA16.19Positive

200DMA19.54Negative

Market Momentum

MACD0.36Negative

RSI47.13Neutral

STOCH50.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:RVU, the sentiment is Negative. The current price of 16.98 is below the 20-day moving average (MA) of 17.27, below the 50-day MA of 17.05, and below the 200-day MA of 19.54, indicating a bearish trend. The MACD of 0.36 indicates Negative momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:RVU.

Ryvu Therapeutics SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PL:RVU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PL:MAB	41Neutral	PLN 127.68M	-2.26	-124.37%	―	56.67%	12.68%
PL:RVU	37Underperform	PLN 392.58M	-5.64	-139.66%	―	-11.57%	43.60%
PL:CTX	34Underperform	PLN 337.20M	-6.83	-132.32%	―	-81.93%	-3.31%

* Healthcare Sector Average

Performance Comparison

PL:RVU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PL:RVU	Ryvu Therapeutics SA	16.98	-7.92	-31.81%
PL:MQR	Pure Biologics SA	1.48	-4.28	-74.34%
PL:CTX	Captor Therapeutics SA	53.00	4.60	9.50%
PL:MOC	OncoArendi Therapeutics SA	5.78	-0.68	-10.53%
PL:MAB	Mabion SA	7.90	-0.36	-4.36%
PL:PTG	PolTREG Spolka Akcyjna	21.30	-4.10	-16.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2025

Ryvu Therapeutics SA AI Stock Analysis